Neurocrine Biosciences’ (NBIX) Outperform Rating Reiterated at William Blair

William Blair restated their outperform rating on shares of Neurocrine Biosciences (NASDAQ:NBIX) in a research note issued to investors on Monday,RTT News reports.

Other equities research analysts have also issued research reports about the company. Jefferies Financial Group increased their price target on Neurocrine Biosciences from $177.00 to $189.00 and gave the company a “buy” rating in a research report on Monday, August 19th. Needham & Company LLC reaffirmed a “hold” rating on shares of Neurocrine Biosciences in a report on Monday, November 11th. StockNews.com cut shares of Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a report on Friday, November 1st. Barclays decreased their price objective on shares of Neurocrine Biosciences from $180.00 to $160.00 and set an “overweight” rating for the company in a research report on Monday, September 9th. Finally, Royal Bank of Canada dropped their target price on Neurocrine Biosciences from $136.00 to $133.00 and set a “sector perform” rating on the stock in a report on Friday, October 4th. Five investment analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Neurocrine Biosciences currently has a consensus rating of “Moderate Buy” and an average target price of $166.00.

Neurocrine Biosciences Trading Down 0.9 %

Shares of NASDAQ NBIX opened at $135.45 on Monday. The stock has a market cap of $13.71 billion, a P/E ratio of 36.31 and a beta of 0.34. The business’s fifty day simple moving average is $123.14 and its 200-day simple moving average is $130.61. Neurocrine Biosciences has a 12-month low of $110.95 and a 12-month high of $157.98.

Insider Buying and Selling at Neurocrine Biosciences

In other Neurocrine Biosciences news, insider Jude Onyia sold 2,331 shares of Neurocrine Biosciences stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $126.29, for a total value of $294,381.99. Following the transaction, the insider now directly owns 15,449 shares in the company, valued at approximately $1,951,054.21. This trade represents a 13.11 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 4.30% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Neurocrine Biosciences

Several hedge funds have recently modified their holdings of the stock. Ashton Thomas Private Wealth LLC purchased a new position in Neurocrine Biosciences during the 2nd quarter worth $28,000. Innealta Capital LLC acquired a new position in shares of Neurocrine Biosciences during the second quarter worth about $30,000. EdgeRock Capital LLC purchased a new position in Neurocrine Biosciences during the second quarter worth about $35,000. Blue Trust Inc. raised its holdings in Neurocrine Biosciences by 171.9% during the third quarter. Blue Trust Inc. now owns 348 shares of the company’s stock worth $40,000 after purchasing an additional 220 shares in the last quarter. Finally, Plato Investment Management Ltd lifted its position in Neurocrine Biosciences by 44.1% in the second quarter. Plato Investment Management Ltd now owns 425 shares of the company’s stock valued at $59,000 after purchasing an additional 130 shares during the period. 92.59% of the stock is owned by institutional investors and hedge funds.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.